作者: 止痛藥 時間: 2025-3-21 23:21 作者: placebo-effect 時間: 2025-3-22 02:47 作者: 要素 時間: 2025-3-22 06:30
Pediatric Pharmacovigilance: Current Practice and Future Perspectives,ype, suspected medicines, age and gender of the child, and type of reporter. Secondly to review experiences with the EU pediatric regulation and its impact on the conduction of pediatric clinical trials in Europe. This literature review showed that occurrence of ADRs in pediatric populations differs作者: Insensate 時間: 2025-3-22 12:43
Detecting Safety Issues in Clinical Trials, is collected and often undergoes a detailed review by the sponsor. Detecting safety issues during a trial has revolved primarily around the Data Safety Monitoring Board (DSMB) who review unblinded summarized data and case reports. Final trial publications typically contain descriptive analyses on t作者: Flatus 時間: 2025-3-22 12:55
Developments and Future Directions of Prescription-Based Observational Cohort Pharmacovigilance,development as compared to during use within routine clinical practice, post marketing. Changes in pharmacovigilance regulations and legislation have given greater weight to the importance of post-marketing observational research and understanding more regarding natural variation in patients and the作者: Flatus 時間: 2025-3-22 18:44
Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigith record databases, traditional insurance claims databases, and distributed data networks. Strengths, weaknesses, considerations, and examples are presented. Finally, the chapter covers the concepts and challenges of data linkage across resources and offers several future perspectives on data avail作者: 緩解 時間: 2025-3-23 00:08 作者: evasive 時間: 2025-3-23 04:30
Patient Reported Outcomes in Pharmacovigilance,first hand from those who have experienced the adverse drug reactions. These experiences are richer in context and information of the impact of an ADR as compared to information from healthcare professionals. New technologies (i.e., Internet) have made the collection of patient reported information 作者: 巨碩 時間: 2025-3-23 08:27
Evidence-Based Pharmacovigilance for Medicines Used in Public Health Programs in Africa,me for International Drug Monitoring having increased from just 5 in the year 2000 to 35 in 2017. However, published information indicates that Africa’s contribution of individual case safety reports (ICSRs) to the WHO ICSR database (VigiBase) is paltry currently standing at less than 1% of the >14 作者: 傻瓜 時間: 2025-3-23 12:27
Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing,ion. The efficacy of drugs is assessed in experimental studies before a drug is allowed on the market in a limited and usually selected group of patients. Therefore, after market authorization the focus is on serious and adverse effects in large groups of patients in daily clinical practice. Observa作者: Morphine 時間: 2025-3-23 16:19 作者: 傳染 時間: 2025-3-23 18:06
Benefit-Risk Assessment in Pharmacovigilance,opulations of patients. Transparent and robust assessments require the use of structured methods, which has sparked lots of research involving both academia and regulatory bodies in recent years. The main aim of this chapter is to provide an overview of the conceptual thinking behind present methods作者: absolve 時間: 2025-3-24 01:54 作者: lethal 時間: 2025-3-24 03:28
1557-2153 itative aspects of Pharmacovigilance.Explores how areas in tThis book examines insights into the latest thinking and core concepts in areas of key methodological endeavor in Pharmacovigilance (PV), which strives to ever more effectively protect patients from harm caused by the medicines they need. E作者: Palpable 時間: 2025-3-24 07:39 作者: 偽證 時間: 2025-3-24 12:33 作者: 決定性 時間: 2025-3-24 17:13
Patient Registries for Safetyness,eal world are different in nature. In this context this chapter investigates patient registries, as a powerful tool for the future of health technology assessment in general and pharmacovigilance in particular.作者: pulse-pressure 時間: 2025-3-24 20:15 作者: V切開 時間: 2025-3-25 00:49 作者: neuron 時間: 2025-3-25 06:46 作者: Trochlea 時間: 2025-3-25 07:45 作者: cumulative 時間: 2025-3-25 13:20
Adam Smith and Economic Progress,expectation is not to provide the reader with an exhaustive account of the field, but rather to support further exploration and stimulate critical review. The chapter concludes with a personal outlook on future challenges and opportunities.作者: Etching 時間: 2025-3-25 16:52 作者: 緊張過度 時間: 2025-3-25 21:27
Risk Management and Minimization,ich remains inadequately explored to date. A framework for the different components of risk management and minimization, as well as practical examples for the evaluation of effectiveness of risk minimization interventions, are presented in this chapter.作者: 能夠支付 時間: 2025-3-26 02:57
Benefit-Risk Assessment in Pharmacovigilance,expectation is not to provide the reader with an exhaustive account of the field, but rather to support further exploration and stimulate critical review. The chapter concludes with a personal outlook on future challenges and opportunities.作者: installment 時間: 2025-3-26 06:30
Book 2018s to ever more effectively protect patients from harm caused by the medicines they need. Each book chapter tends to have a clear quantitative or clinical slant and an aim to provide an overview of methodological insights within a specific topic, while also providing a perspective on how the area is 作者: Brochure 時間: 2025-3-26 11:09 作者: Vertical 時間: 2025-3-26 13:15 作者: 輕觸 時間: 2025-3-26 19:12
Congenital Malformations,arketing of the drug and when used by pregnant women..The optimal method for evaluating the risk of exposure to drugs in pregnancy strongly depends on the stage of drug development. Preapproval data on risks during pregnancy is limited and most information in this phase comes from embryo-fetal toxic作者: 激怒 時間: 2025-3-26 23:47
Pharmacovigilance and the Eye,ology of the eye and how that affects the pharmacology and subsequent toxicity of systemic medications that reach the eye, and then provides a few well-documented and specific examples for reference and understanding of the principles of drug-induced ocular toxicology. This chapter will also address作者: buoyant 時間: 2025-3-27 03:02 作者: 沉思的魚 時間: 2025-3-27 08:29 作者: limber 時間: 2025-3-27 11:33 作者: 口音在加重 時間: 2025-3-27 14:21
Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing,ogress has been made during the past decade in controlling confounding by design and analysis in observational studies. The increasing accessibility of large electronic health record databases has fuelled various international initiatives to analyze multiple databases across countries using common p作者: EWER 時間: 2025-3-27 20:08 作者: Ovulation 時間: 2025-3-28 00:21 作者: 掙扎 時間: 2025-3-28 03:05
Research on Irrigation: Methods and Models,ropic medicine (ATC group N). The EU pediatric regulation has resulted in the establishment of more pediatric clinical trials, but information about whether the regulation has led to more drugs licensed for pediatric use is not available.作者: surrogate 時間: 2025-3-28 07:22
Radiographs and Diagnostic Tests,er of null hypotheses and analyzing the data to look for formal null rejections. Data mining techniques have been applied to adverse event data from clinical trials that include Bayesian hierarchical models and pattern data mining but they have not yet been widely adopted. There is a large potential作者: 補角 時間: 2025-3-28 11:43
https://doi.org/10.1007/978-3-7091-6486-0tunity to collect real world data in relation to these medicines and vaccines. Spontaneous reporting may not necessarily be the best approach in the various African countries considering the high under-reporting associated with all spontaneous reporting schemes globally. However, there are opportuni作者: 內(nèi)疚 時間: 2025-3-28 14:40 作者: 債務(wù) 時間: 2025-3-28 19:38 作者: BOAST 時間: 2025-3-29 01:00 作者: 樣式 時間: 2025-3-29 03:06 作者: 分貝 時間: 2025-3-29 09:47 作者: 和諧 時間: 2025-3-29 11:35 作者: 鬧劇 時間: 2025-3-29 19:07 作者: 完成才會征服 時間: 2025-3-29 20:17 作者: subordinate 時間: 2025-3-29 23:55 作者: amygdala 時間: 2025-3-30 08:00
Franti?ek Balu?ka,Ying-Lang Waned by numerous systemic medications as well as topically administered medications. The eye is often overlooked when thinking of pharmacovigilance because of this relative protection from systemic agents as well as the unfamiliar nature of the eye to many clinicians who are not eye-care providers. Th作者: Notify 時間: 2025-3-30 11:59
Infection Control in the Endodontic Office,d management systems of the China Food and Drug Administration and the differences between conventional medicine and traditional/complementary medicine products, taking drugs used in traditional Chinese medicine as an example. The chapter analyzes and discusses the global use of and regulatory envir作者: 條約 時間: 2025-3-30 13:19
